for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Omeros Corporation

OMER.OQ

Latest Trade

13.01USD

Change

-0.30(-2.25%)

Volume

59,691

Today's Range

13.01

 - 

13.40

52 Week Range

10.30

 - 

20.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.31
Open
13.31
Volume
59,691
3M AVG Volume
10.05
Today's High
13.40
Today's Low
13.01
52 Week High
20.90
52 Week Low
10.30
Shares Out (MIL)
53.34
Market Cap (MIL)
700.38
Forward P/E
-8.98
Dividend (Yield %)
--

Latest Developments

More

Omeros Announces Proposed Public Offering Of Common Stock

Omeros Reports Third Quarter 2019 Financial Results

Omeros Q2 Loss Per Share $0.29

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Omeros Corporation

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Industry

Biotechnology & Drugs

Contact Info

201 Elliott Ave W

+1.206.6765000

http://www.omeros.com

Executive Leadership

Gregory A. Demopulos

Chairman of the Board, President, Chief Executive Officer

Michael A. Jacobsen

Chief Accounting Officer, Vice President - Finance, Treasurer

George A. Gaitanaris

Chief Scientific Officer, Vice President - Science

Peter B. Cancelmo

Vice President, General Counsel, Corporate Secretary

Christopher S. Bral

Vice President - Nonclinical Development

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-1.650

2017

-1.170

2018

-2.610

2019(E)

-1.462
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.98
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-164.96
Return on Equity (TTM)
-94.44

Latest News

Latest News

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

BRIEF-Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy

* FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial

BRIEF-Omeros reports Q1 revenue $12.3 million

* Omeros Corporation reports first quarter 2017 financial results

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

BRIEF-Omeros reports additional positive results from OMS721 Phase 2 trial

* Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up